Market News & Trends
Rezera Advances Ruvonoflast Toward Phase 3 After Positive Phase 2 Inflammation Results
Clinical biotech Rezera (formerly NodThera Inc.) has reported positive topline findings from a Phase 2 study of ruvonoflast, an oral NLRP3 inhibitor being developed for…
Revvity Expands Human-Relevant Cell Model Capabilities With Human Cell Design Acquisition
Revvity is expanding its life sciences portfolio into human-relevant metabolic disease models through an agreement to acquire French biotechnology company Human Cell Design (HCD). The…
Athernal Bio Wins Innovate UK Grant for Early-Stage Leukemia Program
UK biotechnology company Athernal Bio has secured nearly $940,000 in non-dilutive funding from Innovate UK to advance an immunotherapy program aimed at preventing the development…
Evotec Begins Phase 1 Study of Orthopoxvirus Antibody Cocktail
Evotec has moved an investigational orthopoxvirus antibody program into the clinic, with its biologics development and manufacturing arm, Just – Evotec Biologics, initiating a Phase…
HeartBeat.bio, Cubase Bio Team Up to Map Cardiac Fibrosis in 3D
HeartBeat.bio AG and Cubase Bio are joining forces to develop a more detailed way of studying cardiovascular disease in human cardiac tissue, combining organoid models…
Onyx Scientific Invests More Than $2 Million to Expand API Manufacturing Capacity
Onyx Scientific is expanding its small molecule active pharmaceutical ingredient (API) manufacturing operations in Sunderland, UK, with an investment of more than $2 million aimed…
Ionis Receives Approval for First and Only Disease-Modifying treatment for AxD
The FDA has approved Ionis Pharmaceuticals’ ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the first and…
Smart Gel May Pave Way for Next-Gen Drug Delivery
University of Birmingham scientists have developed a new material that changes from a gel to a liquid-like state under ultraviolet light and can be rebuilt…
New Agreement Marks LifeCore’s Thirteenth Late-State Program to Generate Revenue
Lifecore Biomedical, Inc., a fully integrated injectables CDMO, has signed a new agreement to transfer a commercially marketed product to the company's pipeline. Under the…
3 Deaths From Experimental Cell Therapy; Novartis and BMS Pause CGT Trials
Reuters has reported that Novartis paused eight clinical trials of an experiment cell therapy, called rap-cel, targeting autoimmune and neurological disorders, after three patients died.…
Company’s First AI AI-Generated Design Goes Into Human Studies
BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating…
Potential New Target Identified for Cancer Cachexia Therapy
Researchers at Helmholtz Munich, the Heidelberg Faculty of Medicine at Heidelberg University, the German Center for Diabetes Research (DZD) and the Technical University of Munich…
First Patient Dosed in Veloxis Pharmaceuticals Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients
Veloxis Pharmaceuticals, Inc., a global specialty pharmaceutical company part of Asahi Kasei Corporation, today announced that the first participant has been dosed in its Phase…
Pfizer and BioNTech Receive FDA Approval for XFG-Adapted COVID-19 Vaccine
Pfizer Inc. and BioNTech say the FDA has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG…
FDA Approves First-of-a-Kind Drug for Rare Blood Disorder
The Food and Drug Administration today approved Takeda Pharmaceuticals’ Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes…
Lilly’s $2.87B Acquisition of Merida Biosciences Advances Treatments for Autoimmune and Allergic Diseases
Eli Lilly and Company and Merida Biosciences, Inc., a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, announced…
Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
Evonik is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The facility will increase Evonik’s development and…
Centrix Pharma Solutions and University of Sussex partner to advance data-driven pharmaceutical development
Centrix Pharma Solutions, a UK-based Contract Development Manufacturing Organization (CDMO) with strong scientific and manufacturing expertise, has partnered with the University of Sussex on a…
McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
McKesson Corporation announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization…
Hovione Completes Expansion of Loures Tablet Manufacturing Center Adding Commercial-Scale Batch Tableting Capacity
LOURES, Portugal – Hovione, a globally-integrated specialist pharmaceutical CDMO, has completed expansion of the company’s tablet development and manufacturing center at its main global campus…
